Skip to content

Ceribell

US · CBLL #3313 by market cap Listed 2024
23.63 +0.48 +2.07%
Live - 5344 symbols - heartbeat 2s ago · 2026-10-09 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.02 Expensive vs history 93rd percentile
5-year average 2.22 · #101 of 125 in Medical Devices
P/E ratio -13.34 In line with history 56th percentile
5-year average -15.42 · forward -12.79
P/S ratio 8.84 In line with history 51st percentile
5-year average 9.47 · forward 6.89 · #111 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Ceribell (CBLL) 906.87M -13.43 7.07 0.00%
Abbott Laboratories (ABT) 172.35B 32.23 3.37 2.45%
Medtronic (MDT) 113.18B 21.79 2.25 3.22%
Stryker Corp (SYK) 106.38B 28.74 4.43 1.25%
Boston Scientific (BSX) 61.93B 17.30 2.48 0.00%
Edwards Lifesciences (EW) 49.12B 49.54 4.63 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value33.86 Economic moatNone UncertaintyVery High

Trading 43.3% below Morningstar's fair value estimate.

Fair value

CeriBell Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 31% discount to our quantitative fair value estimate of $33.86 per share; however, caution is warranted due to this estimate's very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 7.0 ranks in the bottom 50% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

The company's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 9.2, a core component of leverage, lies in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 19:30:04 · For reference only, not investment advice and not tailored to your situation.

Ceribell discussion 0 comments

Add a comment